Temperature-induced modulation of the cooperative binding of [3H]estriol and [3H]estrone to the estrogen receptor
This sterile, multiple-dose, 30ml vial contains 0.9% benzyl alcohol
Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
MOTS-c improves mitochondrial function for improved energy use, while FTPP causes fat cell death
While initial research suggests potential benefits, it's essential to consult with a healthcare professional before starting any new supplement, especially if you have diabetes
